Pfizer Inc. $PFE Shares Acquired by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 79.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 173,666 shares of the biopharmaceutical company’s stock after acquiring an additional 76,849 shares during the period. Chicago Partners Investment Group LLC’s holdings in Pfizer were worth $5,215,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC increased its holdings in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new stake in Pfizer in the second quarter valued at $26,000. Field & Main Bank bought a new position in Pfizer during the 2nd quarter worth $27,000. Bullseye Investment Management LLC bought a new position in Pfizer during the 2nd quarter worth $28,000. Finally, Timbuktu Capital Management LLC bought a new position in Pfizer during the 2nd quarter worth $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $29.91 on Friday. The stock has a market capitalization of $170.46 billion, a price-to-earnings ratio of 42.72, a PEG ratio of 2.04 and a beta of 0.31. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $31.44. The stock’s 50 day moving average price is $28.72 and its two-hundred day moving average price is $26.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.96 and a current ratio of 1.42.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. The company had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 EPS. On average, equities analysts predict that Pfizer Inc. will post 3.02 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 245.71%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFE. HSBC increased their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. UBS Group upped their target price on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Wednesday. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Royal Bank Of Canada increased their target price on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research report on Wednesday. Finally, Argus set a $40.00 price target on shares of Pfizer in a report on Wednesday. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $29.94.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat adjusted earnings expectations in Q3 and raised its 2026 outlook to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Non-COVID products grew 7% operationally, while launched and acquired products rose 32%, supporting the case that its newer portfolio can offset declines elsewhere. Pfizer Q3 earnings call highlights
• Positive Sentiment: Guggenheim raised its price target from $31 to $33 and assigned a Buy rating; Scotiabank also raised its target and maintained an outperform rating, signaling improving analyst optimism. Guggenheim rating information
• Positive Sentiment: Coverage describes Pfizer’s dividend as well-covered and its valuation as modest, which may appeal to income-focused investors. Pfizer stock looks attractive for income investors
• Neutral Sentiment: Call-option purchases surged well above average, reflecting bullish positioning, though options activity can be speculative and does not establish a sustained outlook.
• Neutral Sentiment: Pfizer is advancing a Phase 3 study of a monthly obesity treatment. Progress could strengthen its pipeline, but the report provides no trial results yet. Pfizer advances monthly obesity drug study
• Neutral Sentiment: Goldman Sachs maintained a Hold rating, a counterpoint to the more positive target changes. Goldman Sachs remains a Hold
• Negative Sentiment: Q3 coverage flagged margin compression. Even with raised guidance and cost reductions, Pfizer must show that new-product growth can translate into durable profitability. Pfizer Q3 deep dive

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.